Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Foliglurax for Levodopa-Induced Dyskinesia in Parkinson's Disease
NCT03331848Phase 2Withdrawn
- Sponsor
- Lundbeck
- Start
- Jan 2018
- Primary completion
- Feb 2019
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial in levodopa-induced dyskinesia (LID) and Parkinson's disease (PD) comparing Placebo with Foliglurax 20mg (2 arms). Primary endpoint: Unified Dyskinesia Rating Scale total score at 26 days. Planned start Jan 2018; status: withdrawn.
02
Drugs
foliglurax
03
Conditions
levodopa-induced dyskinesia (LID)Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT03331848.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03331848.